Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Moeko Ochiai, Eiichi Tanaka, Eri Sato, Eisuke Inoue, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Yoko Higuchi, Rei Yamaguchi, Naoki Sugimoto, Katsunori Ikari, Ayako Nakajima, Hisashi Yamanaka & Masayoshi Harigai. (2021) Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings. Modern Rheumatology 31:4, pages 790-795.
Read now
Read now
Daniel Aletaha, Sonya J Snedecor, Varun Ektare, Mei Xue, Yanjun Bao & Vishvas Garg. (2017) Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. ClinicoEconomics and Outcomes Research 9, pages 451-458.
Read now
Read now
Shunsuke Fukuyo, Kazuyoshi Saito, Kunihiro Yamaoka, Norifumi Sawamukai, Shintaro Hirata, Masao Nawata, Shigeru Iwata & Yoshiya Tanaka. (2014) Efficacy and safety of reducing duration of infliximab infusion. Modern Rheumatology 24:2, pages 275-280.
Read now
Read now
Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi & Carlotta Nannini. (2012) Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics: Targets and Therapy 6, pages 201-206.
Read now
Read now
Hideo Ohtsubo, Sanae Ohkura, Masaki Akimoto, Yoshiya Arishima, Nobuhiko Sunahara, Tomomaro Izumihara, Nobutaka Eiraku, Tamami Yoshitama & Takemasa Matsuda. (2012) An investigation of the correlation between blood concentration of mizoribine and its efficacy in treatment of rheumatoid arthritis based on indices of drug survival and improvement in DAS28-CRP. Modern Rheumatology 22:6, pages 837-843.
Read now
Read now
A Perdriger. (2009) Infliximab in the treatment of rheumatoid arthritis. Biologics: Targets and Therapy 3, pages 183-191.
Read now
Read now
Articles from other publishers (29)
Michael M. Ward, Nima Madanchi, Ali Yazdanyar, Nehal R. Shah & Florina Constantinescu. (2023) Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Chinatsu Takai, Satoshi Ito, Daisuke Kobayashi, Tetsuya Nemoto, Hyunho Lee, Asami Abe, Hiroshi Otani, Kiyoshi Nakazono, Akira Murasawa & Hajime Ishikawa. (2020) Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center. Internal Medicine 59:16, pages 1963-1970.
Crossref
Crossref
Arduino A. Mangoni, Fahdah Al Okaily, Hani Almoallim, Seham Al Rashidi, Reem Hamdy A. Mohammed & Amal Barbary. (2019) Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatology 3:1.
Crossref
Crossref
Lise M Verhoef, Bart JF van den Bemt, Aatke van der Maas, Johanna E Vriezekolk, Marlies E Hulscher, Frank HJ van den Hoogen, Wilco CH Jacobs, Noortje van Herwaarden & Alfons A den Broeder. (2019) Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews 2019:6.
Crossref
Crossref
Emma Simpson, Emma Hock, Matt Stevenson, Ruth Wong, Naila Dracup, Allan Wailoo, Philip Conaghan, Cristina Estrach, Christopher Edwards & Richard Wakefield. (2018) What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment 22:20, pages 1-258.
Crossref
Crossref
Chi-Hua Ko, Jia-Feng Chen, Tien-Tsai Cheng, Han-Ming Lai & Ying-Chou Chen. (2023) Biological Tapering and Sonographic Flare in Rheumatoid Arthritis. Journal of Investigative Medicine 66:2, pages 325-328.
Crossref
Crossref
Christopher J Edwards, Bruno Fautrel, Hendrik Schulze-Koops, Tom W J Huizinga & Klaus Kruger. (2017) Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology 56:11, pages 1847-1856.
Crossref
Crossref
Antoine Vanier, Xavier Mariette, Florence Tubach & Bruno Fautrel. (2017) Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial. Value in Health 20:4, pages 577-585.
Crossref
Crossref
Javier P Gisbert, Alicia C Marín & María Chaparro. (2016) The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 111:5, pages 632-647.
Crossref
Crossref
Bruno Fautrel, Thao Pham, Toni Alfaiate, Frédérique Gandjbakhch, Violaine Foltz, Jacques Morel, Emmanuelle Dernis, Philippe Gaudin, Olivier Brocq, Elisabeth Solau-Gervais, Jean-Marie Berthelot, Jean-Charles Balblanc, Xavier Mariette & Florence Tubach. (2016)
Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial
(STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
. Annals of the Rheumatic Diseases 75:1, pages 59-67.
Crossref
Crossref
Raimon Sanmartí, Susana García-Rodríguez, José María Álvaro-Gracia, José Luis Andreu, Alejandro Balsa, Rafael Cáliz, Antonio Fernández-Nebro, Iván Ferraz-Amaro, Juan Jesús Gómez-Reino, Isidoro González-Álvaro, Emilio Martín-Mola, Víctor Manuel Martínez-Taboada, Ana M. Ortiz, Jesús Tornero, Sara Marsal & José Vicente Moreno-Muelas. (2015) 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. Reumatología Clínica (English Edition) 11:5, pages 279-294.
Crossref
Crossref
Raimon Sanmart?Susana Garc?a-Rodr?guez, Jos? Mar?a ?lvaro-Gracia, Jos? Luis Andreu, Alejandro Balsa, Rafael C?liz, Antonio Fern?ndez-Nebro, Iv?n Ferraz-Amaro, Juan Jes?s G?mez-Reino, Isidoro Gonz?lez-?lvaro, Emilio Mart?n-Mola, V?ctor Manuel Mart?nez-Taboada, Ana M. Ortiz, Jes?s Tornero, Sara Marsal & Jos? Vicente Moreno-Muelas. (2015) Actualizaci?n 2014 del Documento de Consenso de la Sociedad Espa?ola de Reumatolog?a sobre el uso de terapias biol?gicas en la artritis reumatoide. Reumatolog?a Cl?nica 11:5, pages 279-294.
Crossref
Crossref
J. P. Gisbert, A. C. Marín & M. Chaparro. (2015)
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐
TNF
therapy
. Alimentary Pharmacology & Therapeutics 42:4, pages 391-405.
Crossref
Crossref
Arthur Kavanaugh, Susan J Lee, Jeffrey R Curtis, Jeffrey D Greenberg, Joel M Kremer, Lilian Soto, Carol J Etzel, Vanessa Cox, Kazuki Yoshida, George W Reed & Daniel H Solomon. (2015) Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Annals of the Rheumatic Diseases 74:6, pages 1150-1155.
Crossref
Crossref
Peter C. Taylor. 2015. Rheumatology. Rheumatology
492
510
.
Yoshiya Tanaka & Shintaro Hirata. (2014) Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis. Drugs 74:18, pages 2129-2139.
Crossref
Crossref
Paul Emery, Mohammed Hammoudeh, Oliver FitzGerald, Bernard Combe, Emilio Martin-Mola, Maya H. Buch, Marek Krogulec, Theresa Williams, Stefanie Gaylord, Ronald Pedersen, Jack Bukowski & Bonnie Vlahos. (2014) Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine 371:19, pages 1781-1792.
Crossref
Crossref
Noortje van Herwaarden, Alfons A den Broeder, Wilco Jacobs, Aatke van der Maas, Johannes WJ Bijlsma, Ronald F van Vollenhoven & Bartholomeus JF van den Bemt. (2014) Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews.
Crossref
Crossref
I. M. Markusse, G. Akdemir, T. W. J. Huizinga & C. F. Allaart. (2014) Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients’ opinion. Clinical Rheumatology 33:8, pages 1155-1159.
Crossref
Crossref
Kazuki Yoshida, Yoon-Kyoung Sung, Arthur Kavanaugh, Sang-Cheol Bae, Michael E Weinblatt, Mitsumasa Kishimoto, Kazuo Matsui, Shigeto Tohma & Daniel H Solomon. (2014) Biologic discontinuation studies: a systematic review of methods. Annals of the Rheumatic Diseases 73:3, pages 595-599.
Crossref
Crossref
Alfons A den Broeder, Noortje van Herwaarden, Aatke van der Maas, Frank HJ van den Hoogen, Johannes W Bijlsma, Ronald F van Vollenhoven & Bart JF van den Bemt. (2013) Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskeletal Disorders 14:1.
Crossref
Crossref
Yoshiya Tanaka & Shintaro Hirata. (2013) Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?. Clinical Therapeutics 35:12, pages 2028-2035.
Crossref
Crossref
Iris Navarro-Millán, Sebastian E. Sattui & Jeffrey R. Curtis. (2013) Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis. Clinical Therapeutics 35:11, pages 1850-1861.e1.
Crossref
Crossref
Yoshiya Tanaka. (2012) Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Current Opinion in Rheumatology 24:3, pages 319-326.
Crossref
Crossref
A. Picchianti Diamanti, G. Argento, E. Podestà, V. Germano, S. Fazi, A. Migliore, V. David, R. D'Amelio & B. Laganà. (2012) Can the Association of Ciclosporine a and Methotrexate Maintain Remission/Low Disease Activity Induced by Etanercept in Early Rheumatoid Arthritis Patients? Evaluation by Magnetic Resonance Imaging. International Journal of Immunopathology and Pharmacology 25:1, pages 301-305.
Crossref
Crossref
A. Migliore, E. Bizzi, U. Massafra, F. Vacca, L.S. Martin Martin, C. Ferlito, E. Podestà, M. Granata & B. Laganà. (2011) A New Chance to Maintain Remission Induced by Anti-TNF Agents in Rheumatoid Arthritis Patients: CynAR Study II of a 12-Month Follow-up. International Journal of Immunopathology and Pharmacology 24:1, pages 167-174.
Crossref
Crossref
A. W. G. Waugh, S. Garg, K. Matic, L. Gramlich, C. Wong, D. C. Sadowski, M. Millan, R. Bailey, D. Todoruk, R. Cherry, C. W. Teshima, L. Dieleman & R. N. Fedorak. (2010) Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort. Alimentary Pharmacology & Therapeutics 32:9, pages 1129-1134.
Crossref
Crossref
Yoshiya Tanaka. (2010) Achieving drug-free remission: elucidating the role of TNF in rheumatoid arthritisinhibitors. International Journal of Clinical Rheumatology 5:4, pages 391-393.
Crossref
Crossref
Tomoya Miyamura, Koshiro Sonomoto, Masataka Nakamura, Yoshiro Horai, Soichiro Takahama, Hitoshi Ando, Rumi Minami, Masahiro Yamamoto & Eiichi Suematsu. (2009) Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission. Clinical Rheumatology 29:1, pages 87-90.
Crossref
Crossref